C
Chroma Therapeutics
Chroma Therapeutics is focused on the R&D of novel small molecule drugs based on chromatin biology and cell accumulation
About Chroma Therapeutics
Chroma Therapeutics Limited was a UK-based biotechnology firm established around 2000-2001, which has since ceased operations. The company concentrated on the discovery and development of novel small-molecule drugs aimed at treating high-prevalence cancers and inflammatory disorders. Its therapeutic strategy was centered on chromatin biology and proprietary cell accumulation technologies designed to target macrophages.
Read full description
The company's pipeline included Tosedostat (CHR-2797), an oral aminopeptidase inhibitor for leukemia, which it advanced to late-stage clinical studies. Another key program was a macrophage-targeted HDAC inhibitor for cancer, known as CHR-2845. Over its lifespan, Chroma Therapeutics secured significant venture capital backing from prominent investors including Abingworth Management, Gilde Healthcare, The Wellcome Trust, and Nomura Phase4 Ventures. A notable milestone was a 2009 Series D financing round of £15 million, which included a strategic investment from GlaxoSmithKline linked to a collaboration on Chroma's technology platform.
The firm was led by experienced executives from the biotech and pharmaceutical sectors. Ian Nicholson, who has a background in physiology and business, served as CEO from 2004 until 2012, having previously been a Senior Vice President at Celltech. Richard Bungay, a chartered accountant with experience at Celltech and AstraZeneca, held the role of CFO and later took over as CEO in 2012. Despite its clinical progress and strategic partnerships, Chroma Therapeutics ultimately navigated a challenging investment climate, leading to the sale of its assets and closure through a members' voluntary liquidation process around 2012-2014.
At a glance
- Status
- Closed
- Founded
- 2000
- Headquarters
- Winnersh, United Kingdom
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, UKSU, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Chroma Therapeutics.
Funding history
Company financing events and reported valuations.
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Chroma Therapeutics is 170 monthly website visits, up 54.5% over the last three months. Chroma Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Wellcome Trust
Series B and later6 investors entered at this stage
- NVNomura Phase4 Ventures
Gilde Healthcare
Essex Woodlands Health Ventures
GSK- GFGilde IT Fund
Hercules Capital
Other known investors3 additional known investors
Cambridge Enterprise
University of Cambridge
EW Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chroma Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chroma Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.